Compare NPK & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | SGP |
|---|---|---|
| Founded | 1905 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 968.0M |
| IPO Year | 1994 | 2026 |
| Metric | NPK | SGP |
|---|---|---|
| Price | $146.07 | $28.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 75.9K | ★ 100.8K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $152.47 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $91.28 | $17.06 |
| 52 Week High | $158.17 | $30.56 |
| Indicator | NPK | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | N/A |
| Support Level | $121.33 | N/A |
| Resistance Level | $157.42 | N/A |
| Average True Range (ATR) | 4.34 | 0.00 |
| MACD | -0.72 | 0.00 |
| Stochastic Oscillator | 52.94 | 0.00 |
National Presto Industries Inc has an electric product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments, namely Defense, Housewares/Small Appliance, and Safety. The defense segment, which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases, performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While the Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.